Novo Nordisk's new CagriSema obesity drug trial to begin on Feb. 10, clinicaltrials.gov entry shows
Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, according to a www.clinicaltrials.gov entry.
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today
Novo Nordisk (NVO) concluded the recent trading session at $84.03, signifying a -1.36% move from its prior day's close.
US regulator expands Ozempic's use to treat chronic kidney disease
The US Food and Drug Administration (FDA) has approved Novo Nordisk's (NYSE:NVO) Ozempic for treating chronic kidney disease in individuals with type 2 diabetes. It expands the medication's use beyond its role in managing blood sugar levels and weight loss.
Ozempic Receives FDA Approval To Treat Kidney Disease
The Food and Drug Administration on Tuesday approved Ozempic, the weight loss drug made by Novo Nordisk A/S NVO, for the treatment of chronic kidney disease in patients who also have type 2 diabetes.
US FDA approves Novo Nordisk's diabetes drug to reduce risk of worsening kidney disease
Novo Nordisk said on Tuesday the U.S. FDA has approved its diabetes drug Ozempic to reduce the risk of worsening kidney disease and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease.
FDA approves Novo Nordisk's diabetes drug Ozempic for chronic kidney disease, expanding its use
The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S. The FDA's decision means Ozempic can be used to reduce the risk of kidney disease worsening, kidney failure and death from cardiovascular disease in patients with chronic kidney disease and diabetes.
How to Play NVO Stock After New Drug's Success in Obesity Study
The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh in on the stock's growth prospects.
What Does the Future Hold for Eli Lilly?
GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S NYSE: NVO were likely the hottest medical sector story in 2024. With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. NYSE: LLY was another key pharma player in this new type of treatment for diabetes and obesity.
NVO Stock Rises as New Obesity Drug Shows Superior Weight Loss
Novo Nordisk stock gains as its subcutaneous investigational candidate, amycretin, achieves superior weight loss compared to placebo in an obesity study.
Novo Nordisk to cap insulin prices in Minnesota settlement
Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest insulin makers of deceptive pricing practices, court papers on Monday show.
Novo Nordisk shares surge on positive weight loss drug trial results
Novo Nordisk (NYSE:NVO) stock added more than 7% on Friday after the Danish drugmaker unveiled positive early-stage trial results for its weight loss drug amycretin. The trial demonstrated that patients receiving the highest dose of amycretin, a unimolecular long-acting GLP-1 and amylin receptor agonist, achieved an average weight loss of 22% after 36 weeks.
Why Novo Nordisk Stock Jumped a Lucky 7.7% Today
Finally, some good news for Novo Nordisk (NVO 7.30%) shareholders!
